ESMO 2021 Prostate Cancer

REVIEW UroToday

Viewing 1-20 of 74 articles

ESMO 2021: SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer (mHSPC)

ESMO 2021: TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Patients with DDR Gene Mutated Metastatic Castration-sensitive Prostate Cancer (mCSPC)

ESMO 2021: PSMAddition: A Phase III Trial to Compare Treatment with 177Lu-PSMA-617 plus Standard of Care (SOC) Versus SOC Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer

ESMO 2021: A First-in-Human Study of FOR46 in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)

ESMO 2021: PSMAfore: A Phase 3 Study to Compare 177Lu-PSMA-617 Treatment with a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients with mCRPC

ESMO 2021: PRIMORDIUM - A Randomized, International, Trial-in-Progress of Adding Apalutamide to Radiotherapy and an LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer

ESMO 2021: AI, Targeted Data and Predictive Analytics to Monitor and Proactively Manage Patient Outcomes and Validate the Quality and Benefit of Cancer Care

ESMO 2021: How Patients Can Support the Qualitative Empirical Data and Strengthen Cancer Health Research

ESMO 2021: Quality of Life and Long-Term Comorbidities

ESMO 2021: Enhanced Androgen Signalling Inhibition Should Be the Treatment of Choice for Treatment of mCSPC Rather than Docetaxel - Yes

ESMO 2021: Enhanced Androgen Signalling Inhibition Should Be the Treatment of Choice for Treatment of mCSPC Rather than Docetaxel - No

ESMO 2021: The Role of Imaging in Selecting Treatment

ESMO 2021: Evidence-Based Treatment Options in Biochemically Relapsed Prostate Cancer

ESMO 2021: CheckMate 9KD Cohort A2 Final Analysis: Nivolumab + Rucaparib for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

ESMO 2021: Phase Ib/II Study of Sabizabulin (VERU-111), an Androgen Receptor Transport Disruptor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Receptor Targeting Agent

ESMO 2021: Darolutamide Maintenance in Metastatic Castration Resistant Prostate Cancer Previously Treated with Novel Hormonal Agents and Non-Progressive Disease After Subsequent Treatment with a Taxane: SAKK 08/16

ESMO 2021: Health-Related Quality of Life (HRQoL), Pain and Safety Outcomes in the Phase III VISION Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

ESMO 2021: Enhanced Androgen Signaling Inhibition: A Requirement in the Upfront Treatment of Advanced Hormone-Sensitive Prostate Cancer

ESMO 2021: CheckMate 9KD Cohort A2 Final Analysis: Nivolumab + Rucaparib for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ESMO 2021: Phase 1b/2 Study of Sabizabulin (VERU-111), an Androgen Receptor Transport Disruptor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Receptor Targeting Agent

1
2
3
4